Navigation Links
TGen-Scottsdale Healthcare clinical trial finds new class of cancer drugs safe and effective
Date:4/9/2013

SCOTTSDALE, Ariz. April 9, 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen).

Early results from the phase I, first in-human study of an RNA interface (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10, in Washington, D.C. The drug, TKM-080301 (also known as TKM-PLK1) is being developed by Tekmira Pharmaceuticals Corporation.

The study was conducted at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen. It found that the RNAi drug acts by silencing the PLK1 gene involved in tumor growth and can be safely administered in humans. Most patients tolerated the drug well; some showed therapeutic benefit.

"RNAi therapies are a unique approach to cancer treatment as they have the potential to 'turn off' the genes' coding for proteins involved in cancer cell division," said Dr. Ramesh K. Ramanathan, Medical Director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of TGen. "Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth."

TKM-080301 targets a specific gene called polo-like kinase 1 (PLK1), which codes for a protein involved in tumor cell growth. Prior research has shown that high levels of PLK1 are present in many types of cancer, including many of the more aggressive forms.

"Our preclinical results have shown that by decreasing PLK1 levels in cancer cells, we can stop tumor growth and kill the cancer cells," Dr. Ramanathan said.

He and his colleagues have been enrolling patients with advanced solid tumors or lymphoma into the ongoing multicenter, open-label, dose-escalation study. Sequential cohorts of three to six patients have been assigned to escalating doses of TKM-080301 as a 30-minute intravenous infusion. To date, the researchers have assigned 23 patients to the drug at doses ranging from 0.15 mg/kg per week to 0.9 mg/kg per week.

The most common drug-related adverse events have been mild to moderate and include fever, chills, nausea, vomiting and fatigue. Dose-limiting toxicities were observed at the 0.9 mg/kg per-week dose. One patient with a history of asthma experienced shortness of breath and hypoxia; another patient had thrombocytopenia. The researchers subsequently reduced the maximum dose to 0.75 mg/kg per week.

Two patients have been assigned to TKM-080301 for more than six months and have shown no evidence of cumulative toxicity. One of these patients has stable disease and the other has a durable confirmed partial response.

"RNAi therapies, such as the one used in our study, have the potential to make a significant and broad impact on how we treat cancer because we have the ability to target virtually any protein involved in the disease," Ramanathan said. "This approach has the potential to augment the currently available cancer treatments to improve outcomes for the patient."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
2. Coral Calcium Company Announces New Offer Amidst Supreme Court Healthcare Decisions
3. Healthcare researchers recognized at SingHealth Duke-NUS Scientific Congress 2012
4. Daily disinfection of isolation rooms reduces contamination of healthcare workers hands
5. Health inequalities could be reduced by more effective healthcare, says new study
6. Healthcare ethics consultants share lessons learned
7. Kessler Foundation stroke expert receives $145,000 grant from Healthcare Foundation of New Jersey
8. Social environmental factors affect rehospitalization risk in home healthcare patients
9. TGen, Scottsdale Healthcare lead worldwide study of new drug for patients with pancreatic cancer
10. CWRU dental and nursing students collaborate for one-stop healthcare
11. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of ... United States. In 2012, the Biggert-Waters Act was enacted to reflect the actual ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino ... services to communities in the greater Chicago metropolitan area, is embarking on a ... underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one ...
(Date:6/22/2017)... ... June 22, 2017 , ... Branches, Inc. has been ... $245,000 in grant funding to support its programs focused on providing opportunity to low-income ... awarded a grant by the Foundation of $15,000 to support its , Climb to ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National Health ... Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal of ... rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities across ...
(Date:6/22/2017)... , ... June 22, 2017 , ... A June 12 ... to a correspondent concerned about an apparent lack of oral hygiene by an aged ... in geriatrics and dementia-related matters, suggests a number of steps, including scheduling a dentist ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/26/2017)...  In response to the opioid epidemic in ... working with Pfizer to make up to 1 million ... community health centers, free and charitable clinics, public health ... "Pfizer has a long-standing commitment to improving health outcomes ... through educational activities," said Caroline Roan , vice ...
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
Breaking Medicine Technology: